Linical Past Earnings Performance
Past criteria checks 2/6
Linical has been growing earnings at an average annual rate of 13.2%, while the Life Sciences industry saw earnings growing at 28.2% annually. Revenues have been growing at an average rate of 3.3% per year. Linical's return on equity is 8.7%, and it has net margins of 5.4%.
Key information
13.2%
Earnings growth rate
13.3%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | 3.3% |
| Return on equity | 8.7% |
| Net Margin | 5.4% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Linical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 12,518 | 680 | 2,590 | 0 |
| 30 Sep 23 | 12,660 | 714 | 2,605 | 0 |
| 30 Jun 23 | 12,730 | 931 | 2,588 | 0 |
| 31 Mar 23 | 12,516 | 1,004 | 2,509 | 0 |
| 31 Dec 22 | 12,188 | 843 | 2,593 | 0 |
| 30 Sep 22 | 11,953 | 1,006 | 2,484 | 0 |
| 30 Jun 22 | 11,639 | 799 | 2,376 | 0 |
| 31 Mar 22 | 11,555 | 790 | 2,186 | 0 |
| 31 Dec 21 | 11,360 | 906 | 2,086 | 0 |
| 30 Sep 21 | 10,820 | 804 | 2,010 | 0 |
| 30 Jun 21 | 10,639 | 805 | 1,959 | 0 |
| 31 Mar 21 | 10,279 | 539 | 2,016 | 0 |
| 31 Dec 20 | 10,262 | 241 | 2,059 | 0 |
| 30 Sep 20 | 10,527 | 239 | 2,080 | 0 |
| 30 Jun 20 | 10,679 | 268 | 2,180 | 0 |
| 31 Mar 20 | 10,935 | 482 | 2,169 | 0 |
| 31 Dec 19 | 10,944 | 508 | 2,065 | 0 |
| 30 Sep 19 | 11,090 | 409 | 2,057 | 0 |
| 30 Jun 19 | 11,234 | 541 | 2,032 | 0 |
| 31 Mar 19 | 11,313 | 568 | 2,189 | 0 |
| 31 Dec 18 | 10,975 | 853 | 2,254 | 0 |
| 30 Sep 18 | 10,406 | 1,147 | 2,057 | 0 |
| 30 Jun 18 | 9,736 | 1,177 | 1,842 | 0 |
| 31 Mar 18 | 9,113 | 1,295 | 1,511 | 0 |
| 31 Dec 17 | 8,870 | 1,281 | 1,508 | 0 |
| 30 Sep 17 | 8,645 | 1,237 | 1,490 | 0 |
| 30 Jun 17 | 8,541 | 1,381 | 1,444 | 0 |
| 31 Mar 17 | 8,355 | 1,447 | 1,389 | 0 |
| 31 Dec 16 | 8,131 | 1,375 | 1,441 | 0 |
| 30 Sep 16 | 7,916 | 1,331 | 1,425 | 0 |
| 30 Jun 16 | 7,891 | 1,368 | 1,382 | 0 |
| 31 Mar 16 | 7,666 | 1,330 | 1,342 | 0 |
| 31 Dec 15 | 7,420 | 1,154 | 1,310 | 0 |
| 30 Sep 15 | 6,644 | 1,015 | 1,132 | 0 |
| 30 Jun 15 | 5,549 | 579 | 991 | 0 |
| 31 Mar 15 | 4,872 | 437 | 862 | 0 |
| 31 Dec 14 | 4,231 | 465 | 775 | 0 |
| 30 Sep 14 | 4,022 | 429 | 755 | 0 |
| 30 Jun 14 | 3,909 | 445 | 746 | 0 |
| 31 Mar 14 | 3,721 | 449 | 714 | 0 |
| 31 Dec 13 | 3,692 | 473 | 723 | 0 |
| 30 Sep 13 | 3,582 | 481 | 706 | 0 |
| 30 Jun 13 | 3,551 | 515 | 682 | 0 |
Quality Earnings: 2183 has high quality earnings.
Growing Profit Margin: 2183's current net profit margins (5.4%) are lower than last year (6.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2183's earnings have grown by 13.2% per year over the past 5 years.
Accelerating Growth: 2183's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2183 had negative earnings growth (-19.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-19.3%).
Return on Equity
High ROE: 2183's Return on Equity (8.7%) is considered low.